EMA — authorised 20 June 2019
- Marketing authorisation holder: medac Gesellschaft fur klinische Spezialpraparate mbH
- Status: approved
🇪🇺 Trecondi in European Union
EMA authorised Trecondi on 20 June 2019
Marketing authorisations
EMA — authorised 20 June 2019
- Application: EMEA/H/C/004751
- Marketing authorisation holder: medac Gesellschaft für klinische Spezialpräparate mbH
- Local brand name: Trecondi
- Indication: Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.
- Status: approved
Trecondi in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is Trecondi approved in European Union?
Yes. EMA authorised it on 20 June 2019; EMA authorised it on 20 June 2019.
Who is the marketing authorisation holder for Trecondi in European Union?
medac Gesellschaft fur klinische Spezialpraparate mbH holds the EU marketing authorisation.